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ABSTRACT Blocking aVb3 integrin occupancy results in
attenuation of the cellular migration response to insulin-like
growth factor I (IGF-I). To determine whether integrin an-
tagonists alter other IGF-I-stimulated biologic actions, qui-
escent smooth muscle cells (SMCs) were exposed to echistatin
and their ability to respond to IGF-I was determined. Echista-
tin (1027 M) inhibited IGF-I-stimulated DNA synthesis by
80%, and the protein synthesis response also was inhibited.
Therefore blocking occupancy of aVb3 inhibited multiple
target cell actions of IGF-I. To determine whether blocking
aVb3 occupancy could alter IGF-I receptor-mediated signal
transduction, the ability of IGF-I to stimulate phosphoryla-
tion of insulin receptor substrate-1 (IRS-1) was analyzed. A
10-min exposure to 100 ngyml of IGF-I resulted in a substan-
tial increase in phosphorylated IRS-1, and echistatin (1027 M)
blocked the IGF-I-induced IRS-1 phosphorylation response.
Echistatin also attenuated downstream signaling because the
capacity of the p85 subunit of phosphatidylinositol-3 kinase
(PI-3 kinase) to bind to IRS-1 was blocked. In contrast,
exposure of SMCs to vitronectin (1.0 mgycm2) or throm-
bospondin (0.25 mgycm2), two known ligands for aVb3,
resulted in enhancement of the IGF-I-stimulated IRS-1 re-
sponse. To determine whether these effects were caused by
alterations in receptor kinase activity, the IGF-I receptor was
immunoprecipitated and then analyzed for phosphotyrosine.
Echistatin (1027 M) significantly reduced IGF-I-stimulated
tyrosine phosphorylation of the IGF-I receptor b subunit. We
conclude that occupancy of the aVb3 integrin is necessary for
IGF-I to fully activate the kinase activity of the IGF-I receptor
and phosphorylate IRS-1. Activation of the aVb3 receptor
results in an interaction with the IGF-I signal transduction
pathway, which modulates SMCs responsiveness to IGF-I.
Vascular smooth muscle cells (SMCs) have been shown to
contain insulin-like growth factor I (IGF-I) receptors and
respond to IGF-I with increases in DNA and protein synthesis
(1–3), as well as cell migration (4, 5). More recently, IGF-I has
been shown to have an antiapoptotic effect in this cell type (6).
Additionally, IGF-I has been shown to interact with other
stimuli of SMCs replication, such as platelet-derived growth
factor (PDGF), thrombin, and angiotensin-II, to enhance
cellular responsiveness (2, 7, 8). After IGF-I receptor activa-
tion, the heterotetrameric receptor that contains intrinsic
tyrosine kinase activity phosphorylates two proteins that are
important for signal transduction, IRS-1 and IRS-2 (9, 10).
Several lines of experimental evidence have shown that phos-
phorylation of IRS-1 is required for certain IGF-I-mediated
biologic responses (11).
Several other variables have been analyzed to determine
whether they alter IGF-I responsiveness of SMCs and whether
these changes might lead to changes in vessel wall responsive-
ness to IGF-I. Cooperative interactions with other growth
factors, such as PDGF, thrombin, and angiotensin-II have been
analyzed (3–8, 12). Changes in IGF-I receptor number have
been determined, but they are usually minimal and are asso-
ciated with a decrease in IGF-I synthesis and secretion (7).
IGF-binding proteins (IGFBPs) also have been shown to be
important determinants of cellular responsiveness to IGF-I
(13). SMCs have been shown to synthesize and secrete three
forms of IGFBPs, including IGFBP-2, -4, and -5 (14). IGFBP-2
can act as a weak stimulator of IGF-I action in the presence of
high concentrations of IGF-I (15). IGFBP-4, in contrast, is
usually a negative regulator of IGF-I action (16, 17). Responses
to IGFBP-5 are biphasic in that, when a low concentration of
this material is associated with extracellular matrix, it can act
to enhance IGF-I actions, whereas when a high concentration
of intact, nonproteolytically cleaved protein is present in
interstitial f luids, it acts to inhibit IGF-I binding to receptors
and inhibits IGF-I actions (18, 19).
In previous studies, we have determined that integrin occu-
pancy is necessary for SMCs to migrate optimally in response to
IGF-I (20). aVb3 occupancy appears to be very important for the
cellular migration response to IGF-I because these cells will
migrate in the absence of serum if vitronectin alone is added to
the culture plates (21) and blocking matrix protein occupancy of
the aVb3 receptor using specific aVb3 antagonists, such as
echistatin, results in attenuation of the SMCs migration response
to IGF-I (21). That there could be an interaction between the
aVb3-signaling pathway or proteins that associate with the aVb3
within the focal adhesion complex and elements in the IGF-I
receptor signal transduction pathway is suggested by several
reports. Uvori and Rhouslahti (22) reported that IRS-1 binds to
aVb3 after insulin receptor activation in a rat fibroblast and a
pancreatic tumor cell line. In a different test system, Miyamoto,
et al. (23) showed that focal clustering of b1 integrins within the
focal adhesion complex led to enhanced PDGF receptor phos-
phorylation in response to growth factor stimulation. More
recently, Senger et al. (24) showed that angiogenesis promoted
by vascular endothelial growth factor was regulated through
a1b1 and a2b1 integrins. These findings suggest that there may
be direct interactions between growth factor receptor-
signaling pathways and signaling elements that are activated by
integrin occupancy; therefore, we attempted to determine
whether altering ligand occupancy of aVb3 would alter IGF-I
receptor signaling.
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Materials. Human IGF-I and des 1–3 IGF-I were purchased
from Bachem. Poly(vinylidene diflouride) (PVDF) filters were
purchased from Millipore. Autoradiographic film was ob-
tained from Eastman Kodak. Fetal bovine serum, DMEM,
penicillin, and streptomycin were purchased from Life Tech-
nologies, Grand Island, NY. Trypsin was obtained from Boehr-
inger Mannheim. The anti-phosphotyrosine antibody (PY20)
was obtained from Transduction Laboratories, Lexington, KY.
An anti-phosphatidylinositol-3 kinase (PI-3 kinase) antibody
(P-85 subunit) and an anti-IRS-1 antibody were purchased
from Upstate Biotechnology, Lake Placid, NY. An anti-IRS-2
antibody was kindly provided by Morris White, Joslin Diabetes
Center, Boston. Anti-aV antiserum was purchased from
Chemicon. Laminin, type IV collagen, echistatin, insulin, and
thrombospondin were purchased from Sigma. [3H]Thymidine
was purchased from ICN. A polyclonal antibody that was
specific for the IGF-I receptor b subunit was purchased from
Santa Cruz Biotechnology. [35S]Methionine was purchased
from New England Nuclear. Tissue culture plastic ware was
purchased from Falcon Labware.
Methods. Porcine aortic smooth muscle cells (pSMCs) were
obtained from explants of thoracic aortas from young pigs by
using a previously described method (25). The cells that
migrated from the explants were maintained and cultured in
DMEM supplemented with glucose (4.5 gmyliter), penicillin
(100 unitsyml), streptomycin (100 mgyml), glutamine (4
mmol), and 10% fetal bovine serum in 10-cm tissue culture
plates (Falcon 3001). The cells were used between passages 4
and 12. These cells were subcultured after trypsinization on
either 24-well plates or 96-well microtiter plates in DMEM
supplemented with 10% fetal bovine serum. For the protein
synthesis experiments, the cells were plated at 5,000 cellsycm2.
After one medium change, they were incubated for an addi-
tional 3 days and then used. For DNA synthesis experiments,
the cells were plated at 5,000 cells per culture well in 96-well
plates and cultured for 5 days without a medium change. To
determine changes in IRS-1 phosphorylation, the cultures
were seeded at 5,000 cellsycm2 on 10-cm culture dishes and
then grown to confluency for '7 days with one medium
change. In some experiments, the cells were plated on vitro-
nectin (1.0 mgycm2) or thrombospondin (0.25 mgycm2), or
laminin (1.0 mgycm2) plus type IV collagen (5.0 mgycm2) at
10,000 cellsycm2 in serum-free DMEM and allowed to attach
for 4 hr before initiation of the experiment.
Immunoprecipitation of IRS-1, IRS-2, PI-3 Kinase (P85
Subunit,) and IGF-I Receptor. To analyze the phosphorylation
of IRS-1 and the IGF-I receptor, pSMCs cultures in 10-cm
plates were serum deprived for 12 hr in the presence of
echistatin (1028 or 1027 M). They were then exposed to IGF-I
(100 ngyml), insulin (10 mgyml or 10 ngyml), or fresh DMEM
alone for 10 min at 37°C. The cells were then scraped into 1 ml
of lysis buffer (1% Nonidet P-40y0.25% sodium deoxy-
cholatey1 mM EGTAy150 mM NaCly50 mM TriszHCL, pH
7.5y1 mM sodium vanadatey1.0 mM NaFy1.0 mM PMSFy1
mg/ml pepstatiny1 mg/ml leupeptiny1.0 mg/ml aprotinin)
termed RIPA buffer and centrifuged at 15,000 3 g for 10 min.
The proteins in the supernatant were then exposed to a 1:300
dilution of rabbit anti-IRS-1, a 1:100 dilution of rabbit anti-
IRS-2, or a 1:500 dilution of rabbit anti-IGF-I receptor anti-
body for 14 hr at 4°C. The immune complexes were precipi-
tated by the addition of protein A-Sepharose as previously
described (18). The precipitates were analyzed by SDSyPAGE
(7.5%) and then transferred to an Immobilon PSQ, 0.45-mm
pore size filter (Millipore). Immunoblotting for phosphoty-
rosine was carried out by using a 1:1,000 dilution of (PY20)
(Transduction Laboratories) anti-phosphotyrosine antibody.
In some experiments, the filters were immunoblotted for IRS-1
or IGF-I receptor by using 1:500 dilutions of the two antisera
that were used for immunoprecipitation. The immune com-
plexes were detected by enhanced chemiluminescence by using
the method as previously described (18).
Ligand occupancy of the a2b1 integrin was stimulated by
plating the cells on culture dishes that had been coated in
laminin (1.0 mgycm2) and type IV collagen (5.0 mgycm2). The
aVb3 integrin was stimulated by plating the cells on plates that
had been coated with vitronectin by using a concentration of
1 mgycm2 or adding 2.0 mgyml of vitronectin to the serum free
medium for 4 hr and then determining the capacity of IGF-I
to stimulate IRS-1 phosphorylation as described. To deter-
mine whether the p85 subunit of PI-3 kinase would bind to
IRS-1, the IRS-1 immunoprecipitates were analyzed for the
presence of p85 by incubating the immunoblots of the immu-
noprecipitates with a 1:1,000 dilution of anti-p85 antiserum.
Measurement of [3H]Thymidine Incorporation into
pSMCs. pSMCs were plated at 5,000 cellsycm2 on 96-well
culture plates. After 5 days, the cultures were exposed to
increasing concentrations of IGF-I (2–50 ngyml) in the pres-
ence or absence of echistatin (1028 or 1027 M) and fresh
DMEM-H (0.2 ml) supplemented with 0.2% human platelet-
poor plasma and 0.5 mCi of [3H]thymidine (specific activity 35
Ciymmol). In some experiments, soluble vitronectin (2 mgyml)
also was added to the plates. After a 36-hr incubation, the
plates were placed on ice and washed twice with cold phos-
phate-buffered saline and then incubated with cold 5% tri-
chloroacetic acid for 10 min. The trichloroacetic acid precip-
itable material was solubilized in 0.1 ml of 0.1% SDSy0.1 M
NaOH, and the radioactivity was quantified in the Beckman
Scintillation Counter by using ScintiSafe Eco II (Fisher Sci-
entific) as a scintillant.
Measurement of Protein Synthesis. pSMCs were grown to
confluence in 24-well culture plates (Falcon 3036). The cul-
tures were rinsed once with serum free DMEM and incubated
with 0.25 ml of low (1027 M) methionine MEM (a mixture of
10% DMEM and 90% methionine-free DMEM) for 6 hr in the
presence of 50 mCi per well of [35S]methionine (specific
activity 1,206 Ciymmol). Additional wells also received IGF-I
(0–20 ngyml) and various concentrations of echistatin between
1029 and 1027 M. After 6 hr the amount of [35S]methionine
that had been incorporated into total protein was determined
by using the extraction method described previously and
scintillation counting.
Preparation of Vitronectin. Porcine vitronectin was pre-
pared from porcine plasma by using a previously described
method (26). Purity was proven by SDSyPAGE with silver
staining, which showed a single band at 67 kDa. This band was
FIG. 1. [3H]Thymidine incorporation response to IGF-I and
echistatin. Quiescent pSMCs cultures were stimulated with increasing
concentrations of IGF-I (F—F) and the amount of [3H]thymidine that
was incorporated into DNA determined as described in Materials and
Methods. Additional cultures also were exposed to echistatin 1027 M
(h—h) plated on vitronectin (2.0 mgywell) (■—■) or plated on
vitronectin and exposed to echistatin (E—E). Each point represents
the mean of triplicate determinations.






















proven to be vitronectin by immunblotting using a 1:1,000
dilution of a polyclonal antibody that was purchased from
Sigma.
RESULTS
DNA Synthesis Responses of SMCs to IGF-I. The addition of
increasing concentrations of IGF-I resulted in a 3.8-fold increase
in [3H]thymidine incorporation into DNA compared with control
cultures (Fig. 1). If the cultures were plated on vitronectin before
initiation of the experiment, the response to IGF-I was enchanced
(1.5-fold increase), suggesting that ligand binding to aVb3 mod-
ulates IGF-I stimulation of the cellular DNA synthesis response.
To further confirm this conclusion, increasing concentrations of
IGF-I were added with 1027 M echistatin. As shown in Fig. 1,
echistatin resulted in 80% inhibition of the ability of IGF-I (20
ngyml) to stimulate DNA synthesis. If the cells were plated on
vitronectin, echistatin inhibited their response by 86%. Impor-
tantly, this concentration of echistatin did not inhibit cell attach-
ment, and it had no effect on basal [3H]thymidine incorporation.
To further prove that these effects were specific, the responses to
human serum or PDGF were assessed in the presence of echista-
tin. Echistatin concentrations as high as 1027 M had no effect on
the [3H]thymidine incorporation response to 10% serum (Table
1). There was a significant effect on the response to 20 ngyml of
PDGF but only a 27% reduction in this response was noted.
Stimulation of Protein Synthesis. To further document the
effects of blocking ligand occupancy of the aVb3 receptor on
IGF-I actions, the effect of increasing concentrations of
echistatin on the ability of IGF-I to stimulate protein synthesis
was determined. As shown in Table 2, the addition of IGF-I
between 0 and 20 ngyml stimulated a 2.4-fold increase in
[35S]methionine incorporation into protein. In contrast, if
echistatin was added at 1027 M, the response to IGF-I was
inhibited by 94%, and 1029 M resulted in a statistically
significant reduction.
Inhibition of Ligand Occupancy of aVb3 Results in De-
creased IGF-I-Stimulated IRS-1 Phosphorylation. To deter-
mine whether these effects of echistatin were mediated
through an alteration in IGF-I receptor-mediated signal trans-
duction, confluent, quiescent cultures were exposed to IGF-I
alone or the combination of IGF-I plus either 1028 or 1027 M
echistatin for 10 min. Echistatin was added 12 hr before the
addition of IGF-I. After a 10-min incubation at 37°C, the cells
were lysed and IRS-1 was immunoprecipitated, and then the
immunoprecipitated proteins were separated by SDSyPAGE
and immunoblotted for phosphotyrosine. IGF-I stimulated
tyrosine phosphorylation of a band with an Mr estimate of 175
kDa (Fig. 2A). The band was shown to be IRS-1 by immuno-
blotting (Fig. 2B). The addition of 1028 M echistatin resulted
in a 35% inhibition of signal intensity of tyrosine phosphory-
lated IRS-1, and 1027 M resulted in .70% inhibition (Fig. 2A).
The control immunoblot for IRS-1 abundance showed that the
signal intensity was nearly identical in all lanes. To further
determine whether modulation of aVb3 occupancy would
affect the ability of IGF-I to induce IRS-1 phosphorylation,
SMCs were plated on vitronectin or thrombospondin coated
plates for 4 hr to allow cell attachment and then stimulated
with IGF-I. Exposure to vitronectin or thrombospondin re-
sulted in major increases in the degree of tyrosine phosphor-
ylation of IRS-1 in response to IGF-I. Compared with cultures
that were plated on lamininytype IV collagen, which bind to
the a2b1 integrin, the IGF-I-induced increase in IRS-1 phos-
phorylation was enhanced by 2.4-fold (vitronectin) and 2.2-
FIG. 2. Effects of echistatin on tyrosine phosphorylation of IRS-1
after IGF-I stimulation. Subconfluent SMCs were incubated without
echistatin (lanes 1 and 2) or with echistatin at 1028 M (lane 3) or 1027
M (lane 4) for 12 h in serum-free DMEM-H. The cells were exposed
to no IGF-I (lane 1) or 100 ngyml IGF-I (lanes 2–4) for 10 min. They
were lysed with 1 ml of RIPA buffer, and the lysates were immuno-
precipitated by using an anti-IRS-1 antiserum as described in Materials
and Methods. The precipitated proteins were separated by 7.5%
SDSyPAGE and transferred to a PVDF membrane. The membrane
was blotted with anti-phosphotyrosine antibody (A) or an antibody
against IRS-1 (B).
FIG. 3. Effect of ECM proteins on tyrosine phosphorylation of
IRS-1. SMCs were cultured on laminin plus type IV collagen (lanes 1
and 2) or vitronectin (lanes 3 and 4). In a second experiment, they were
plated on laminin plus type IV collagen (lanes 5 and 6) or throm-
bospondin (lanes 7 and 8) for 4 h as previously described. The cells
were then exposed to no IGF-I (lanes 1, 3, 5, and 7) or 100 ngyml IGF-I
(lanes 2, 4, 6, and 8) for 10 min. The cells were lysed, and the lysates
were immunoprecipitated by using an antiserum against IRS-1. The
precipitated proteins were separated by 7.5% SDSyPAGE and trans-
ferred to a PVDF membrane. The membrane was blotted with an
anti-phosphotyrosine antibody. The results expressed as scanning
units are: lane 2, 10457; lane 4, 25326; lane 6, 9789; and lane 8, 21030.
Table 1. DNA synthesis response to serum or PDGF
[3H]Thymidineyincorporation, CPM
Human serum 10% 39543 6 3886
1Echistatin 1028 M 38774 6 4107
1Echistatin 1027 M 38662 6 3943
PDGF 30 ngyml 28986 6 3011
1Echistatin 1028 M 24621 6 2462
1Echistatin 1027 M 22499 6 2776
Platelet-poor plasma 4539 6 492
The results are the mean 6 SD of triplicate determinations in three
separate experiments.




Control 3937 6 504
IGF-I 10 ngyml 5719 6 499
IGF-I 20 ngyml 6943 6 821
IGF-I 50 ngyml 8862 6 669
IGF-I 50 ngyml 1 echistatin 1029 M 7318 6 801
IGF-I 50 ngyml 1 echistatin 1028 M 5004 6 662
IGF-I 50 ngyml 1 echistatin 1027 M 4001 6 390
Echistatin 1027 M 3788 6 422
The results are the mean 6 SD of triplicate determinations in two
separate experiments.






















fold (thrombospondin). Insulin, at 10 mgyml, also stimulated
the phosphorylation of IRS-1, and the insulin-induced increase
in phosphorylation was inhibited by exposure to 1027 M
echistatin. Because high concentrations of insulin will interact
with the IGF-I receptor, we tested the effect of 10 ngyml of
insulin. This concentration failed to stimulate the phosphor-
ylation of IRS-1 (Fig. 4).
To further define the mechanism by which this interaction
occurred, we exposed the cultures to IGF-I or IGF-I plus
echistatin (1028 or 1027 M) and then immunoprecipitated the
IGF-I receptor from the cell lysates. As shown in Fig. 5, IGF-I
stimulated phosphorylation of the b subunit of the receptor,
and this response was inhibited by 70% with 1027 M echistatin.
A control immunoblot showed that similar amounts of the
IGF-I receptor were immunoprecipitated. Although 100
ngyml IGF-I was used, in additional experiments we deter-
mined that 25 and 50 ngyml were equipotent in stimulating
tyrosine phosphorylation of IGF-I receptor. The addition of
similar concentrations of des 1–3 IGF-I stimulated the tyrosine
phosphorylation of the receptor to the same extent compared
with native IGF-I (data not shown). To determine whether
blocking IGF-I receptor phosphorylation would alter phos-
phorylation of IRS-2, another important substrate of the
receptor tyrosine kinase, IRS-2 phosphorylation was mea-
sured following cellular exposure to IGF-I or IGF-I plus
echistatin. As shown in Fig. 6, IRS-2 phosphorylation also was
inhibited by echistatin. To determine whether echistatin ex-
posure would alter downstream signaling, we determined the
capacity of the p85 subunit of PI-3 kinase to bind to IRS-1 after
cellular exposure to IGF-I or IGF-I plus echistatin. As shown
in Fig. 7, p85 binding to IRS-1 was inhibited by echistatin
exposure. To investigate the possibility that the effect of
echistatin was due to blocking a direct physical association
between IRS-1 or the IGF-I receptor and aVb3, we attempted
to determine whether IRS-1 or the IGF-I receptor and aVb3
would coprecipitate after IGF-I stimulation. The cell lysates
were immunoprecipitated with anti aV antiserum then immu-
noblotted for IRS-1 or the IGF-I receptor. Both experiments
were repeated three times, but in no case, were we able to
demonstrate coprecipitation by using the same conditions that
were effective for altering IRS-1 and IGF-I receptor phos-
phorylation.
FIG. 4. Effects of echistatin on tyrosine phosphorylation of IRS-1
after insulin stimulation. Subconfluent SMCs were incubated without
echistatin (lanes 1, 2, and 4) or with echistatin at 1027 M (lane 3) for
12 hr in serum-free DMEM-H. The cells were exposed to no insulin
(lane 1) or 10 mgyml insulin (lanes 2 and 3) or 10 ngyml insulin (lane
4) for 10 min. After lysis with 1 ml of RIPA buffer, the lysates were
immunoprecipitated by using an anti-IRS-1 antiserum as described in
Materials and Methods. The precipitated proteins were separated by
7.5% SDSyPAGE and transferred to a PVDF membrane. The mem-
brane was blotted with anti-phosphotyrosine antibody.
FIG. 5. Effect of echistatin on tyrosine phosphorylation of IGF-I
receptor after IGF-I stimulation. Subconfluent SMCs were incubated
without echistatin (lanes 1 and 2) or with echistatin at 1028 M (lane
3) and 1027 M (lane 4) for 12 h in serum-free DMEM-H. The cells
were exposed to no IGF-I (lane 1) or 100 ngyml IGF-I (lanes 2–4) for
10 min. The cells were lysed, and the lysate was immunoprecipitated
by using an anti-IGF-I receptor b subunit antiserum. The precipitated
proteins were separated by 7.5% SDSyPAGE and transferred to a
PVDF membrane. The membrane was blotted with an antibody
against phosphotyrosine (A) or an antibody against IGF-I receptor b
subunit (B).
FIG. 6. Effect of echistatin on tyrosine phosphorylation of IRS-2
after IGF-I stimulation. Subconfluent SMCs were incubated without
echistatin (lanes 1 and 2) or with echistatin at 1027 M (lane 3) for 12 h
in serum-free DMEM-H. The cells were exposed to no IGF-I (lane 1)
or 100 ngyml (lanes 2 and 3) for 10 min. They were then lysed with 1
ml of RIPA buffer, and the lysates were immunoprecipitated by using
an anti-IRS-2 antiserum as described in Materials and Methods. The
precipitated proteins were separated by 7.5% SDSyPAGE and trans-
fered to a PVDF membrane. The membrane was blotted with anti-
phosphotyrosine antibody (A) or an antibody against IRS-2 (B).
FIG. 7. Effect of echistatin on the association of IRS-1 and PI-3
kinase. Subconfluent SMCs were incubated without echistatin (lanes
1 and 2) or with echistatin at 1028 M (lane 3) and 1027 M (lane 4) for
12 h in serum-free DMEM-H. The cultures were then exposed to no
IGF-I (lane 1) or 100 ngyml IGF-I (lanes 2, 3, and 4) for 10 min. They
were lysed, and the lysate was immunoprecipitated by using an
anti-IRS-1 antiserum. The precipitated proteins were separated by
7.5% SDSyPAGE and transferred to a PVDF membrane. The mem-
brane was blotted with an anti-P-85 antibody as described in Materials
and Methods.























The results of this study clearly demonstrate that blocking
ligand occupancy of aVb3 results in attenuation of SMCs
responsiveness to IGF-I. Although it might be predicted that
blocking aVb3 occupancy would inhibit IGF-I-stimulated cell
migration simply by blocking physical contact of aVb3 with
extracellular matrix proteins, which has been postulated to be
necessary for the physical forces that mediate migration, it was
not intuitively obvious that blocking ligand occupancy of this
receptor would inhibit other IGF-I-stimulated responses.
Therefore, we tested whether blocking ligand occupancy of
aVb3 would block the IGF-I stimulation of protein and DNA
synthesis. These responses were inhibited by echistatin, a
known competitive antagonist of aVb3 ligand occupancy in
this cell type. Importantly, echistatin had no effect on basal
[3H]thymidine or [35S]methionine incorporation. It also had no
effect on the serum stimulated responses, suggesting that this
inhibition was not a result of direct cytotoxicity. Similarly, cell
detachment was not observed. These results suggested that
there was a specific interaction between activation of the aVb3
integrin receptor and the IGF-I receptor-mediated signal
transduction pathways.
To determine whether this was the case, we analyzed the
effect of blocking aVb3 occupancy on the phosphorylation of
the b subunit of the IGF-I receptor and IRS-1. IRS-1 is the
most proximal element in the IGF-I receptor signal transduc-
tion pathway. It has been shown to be directly phosphorylated
on tyrosines by the IGF-I receptor tyrosine kinase in response
to IGF-I receptor ligand occupancy (9, 11, 27), and the degree
of phosphorylation is dependent on the degree of stimulation
of intrinsic tyrosine kinase activity of the receptor (27). In this
study, we demonstrate that concentrations of echistatin, for
example 1027 M, that are effective in inhibiting ligand activa-
tion of aVb3 in this cell type (20) are also effective in inhibiting
optimal activation of the IGF-I receptor tyrosine kinase,
IRS-1, and IRS-2. This implies that an interaction involving
activation of the aVb3 receptor and the IGF-I-signaling
pathway is required for IGF-I to fully stimulate its anabolic
effects. This was further confirmed by showing that plating the
cells on a matrix that was enriched in vitronectin resulted in
augmentation of the cellular DNA synthesis response to IGF-I
above what could be achieved by maintaining the cells in 0.2%
serum, and augmentation of the IRS-1 phosphorylation re-
sponse to IGF-I also was observed. Because we have shown
previously that 0.2% serum or vitronectin must be present for
these cells to respond to IGF-I with increased migration (21),
this suggests that augmentation of IRS-1 phosphorylation by
ligand occupancy of aVb3 is required for all pSMCs responses
to IGF-I.
The molecular mechanism by which aVb3 receptor occu-
pancy augments IGF-I stimulation of IRS-1 phosphorylation
was addressed in these studies. Uvori and Rhouslahti (22)
reported that activation of the insulin receptor in fibroblasts
that had been transfected with the insulin receptor and a
pancreatic tumor cell line that had been transfected with aV
led to binding of phosphorylated IRS-1 to aVb3 and that
ligand occupancy of both receptors was required for this
binding event to occur. We attempted to demonstrate copre-
cipitation of activated aVb3 and the IGF-I receptor and IRS-1
but were unsuccessful. Specifically, we treated cells with
increasing concentrations of IGF-I and showed that IRS-1 and
the receptor were phosphorylated, but we were unable to
coprecipitate by using an antibody that has been shown
previously to coprecipitate IRS-1 with other proteins, such as
PI-3 kinase, in this test system (11, 18). This difference
between our findings and those of Uvori and Rhoushalti may
be because of the fact that we used nontransfected cells that
had a lower IGF-I receptor number. Our results suggest that
in our nontransfected SMCs there is no direct physical asso-
ciation between aVb3 and the IGF-I receptor.
Studies by Miyamato and coworkers (23) showed that the
degree of epidermal growth factor, PDGF, or fibroblast
growth factor receptor tyrosine phosphorylation could be
enhanced if b1 integrin occupancy was stimulated. Specifically,
these investigators activated unidentified b1 integrins by plat-
ing cells on anti-b1 antibody-coated beads and measuring
tyrosine phosphorylation of the receptors in response to
growth factor stimulation. They did not report coimmunopre-
cipitation of the receptors and b1 integrins but postulated that
there is a close physical association of the two types of
receptors within the focal adhesion complex. They proposed
that clustering of b1 integrins leads to enhanced ligand induced
activation of these growth factor receptors, possibly due to
enhanced transphosphorylation within the focal adhesion
complex (23). Other structural elements of the focal adhesion
complex that have been shown to localize under such condi-
tions include SRC kinase, focal adhesion kinase, PI-3 kinase,
and cytoskeletal proteins such as vincullin and tallin (28, 29).
Because we were unable to detect binding of aVb3 to the
IGF-I receptor, this suggests that the mechanism proposed by
Miyamoto et al. (23) by which ligand induced clustering of
integrins activates growth factor receptor tyrosine kinases is
the most likely explanation for our findings.
To determine whether IGFBPs are involved in the alteration
of IGF-I signaling, the IGF-I receptor phosphorylation re-
sponse to 25 and 50 ngyml of IGF-I was analyzed. These lower
concentrations were equally effective, and des 1–3 IGF-I, an
IGF-I analog, that binds to IGF-I receptor but binds weakly to
IGFBPs induced a similar response. These results show that
under the conditions used in these experiments, it is unlikely
that IGFBPs contribute to the altered IGF-I signaling.
We also investigated the activation of the downstream-
signaling element, PI-3 kinase. Blocking aVb3 occupancy
blocked the binding of the P85 subunit of PI-3 kinase to IRS-1,
suggesting that its activation can be modulated by aVb3. Myers
et al. (11) have shown p85 binding to IRS-1 after IGF-I
receptor activation. Two signaling pathways are generally
stimulated by IGF-I receptor activation. These include the
Grb-2 mitogen-activated protein kinase activation pathway,
which is necessary for growth stimulation by IGF-I and the
PI-3 kinase protein tyrosine kinase B pathway, which has been
shown to be necessary for activating the transcription of
specific genes in response to IGF-I (30, 31). Whether the three
processes that we have shown to be sensitive to aVb3 blockade
utilize one or both of these pathways has not been determined.
However other investigators have determined clearly that the
Grb-2-mitogen-activated protein kinase pathway is necessary
for mitogenesis to proceed normally (32), and PI-3 kinase
activation is necessary to stimulate membrane ruffling, an
important component of the cell migration response (33). This
suggests that blocking IRS-1 phosphorylation in this cell type
may affect signaling through both pathways, but this remains
to be definitively determined.
The molecular mechanism by which aVb3 actually functions
to alter IGF-I receptor phosphorylation could be mediated
through multiple types of interactions. Because these two
proteins do not appear to coimmunoprecipitate, it is possible
that these elements colocalize with focal adhesion complexes.
It is also possible that aVb3 occupancy by echistatin directly
affects an intermediary protein that binds to the IGF-I recep-
tor that interacts directly with the tyrosine kinase domain to
limit its ability to phosphorylate IRS-1 or that it binds directly
to IRS-1 and limits its ability to function as a substrate. A
candidate protein would be integrin-activating protein. Inte-
grin-activating protein is a transmembrane protein that has
been shown to be activated after aVb3 occupancy and binds
specifically to aVb3 (34). At present, it is not known whether
SMCs contain an integrin activating protein, but if they do, this






















would be a candidate protein for mediating the interaction
between aVb3 and IRS-1 or between aVb3 and the tyrosine
kinase subunit of the IGF-I receptor.
Although blocking aVb3 occupancy had some effect on
PDGF responsiveness of the cells, this effect was not as great
as that shown with IGF-I. This result suggests that different
growth factors may be sensitive to blocking ligand occupancy
of different and specific integrins. Ross and coworkers (35)
have shown that blocking the a2b1 occupancy reduces cell
migration response to PDGF. On the other hand, because
vascular SMCs are essentially devoid of insulin receptors (36),
the phosphorylation of IRS-1 induced by 10 mgyml insulin may
be due to the interaction of insulin with the IGF-I receptor.
This was further confirmed by showing that 10 ngyml, a
concentration of insulin that activates only the insulin receptor,
failed to stimulate the phosphorylation of IRS-1.
Ligand occupancy of aVb3 is a particularly attractive can-
didate for analysis because it is expressed in the SMCs within
vessel walls and because blocking its occupancy appears to
have some effect on the progression of atherogenesis (36).
Several extracellular matrix proteins that bind avidly to aVb3
are also present within atherosclerotic lesions. Two that appear
to be increased within lesions are thrombospondin and os-
teopontin (38, 39). Thrombospondin is a complex protein that
has multiple-binding domains, one of which interacts with
aVb3 and one of which interacts directly with integrin acti-
vating protein (34, 39). This suggests that stimulation by
thrombospondin binding would result in full activation of
aVb3. Thrombospondin expression is enhanced during for-
mation of the neointima (40). Because our data show that
thrombospondin augments IGF-I stimulated phosphorylation
of IRS-I in cultured SMCs, this may provide a mechanism by
which this matrix protein contributes to the formation of
neointima.
In summary, we have demonstrated that ligand occupancy of
aVb3 is required for full activation of the IGF-I receptor b
subunit and the signal transduction element, IRS-1, by IGF-I
stimulation of its receptor. In addition, we have demonstrated
that this blockage leads to global inhibition of IGF-I action in
this cell type. This suggests that blocking ligand occupancy of
aVb3 may inhibit cellular mitogenesis and anabolic response
mechanisms that depend on growth factor-mediated pathways
and that cooperativity between the integrin receptor occu-
pancy and growth factor receptor occupancy is an important
component of the cellular response to injury. Future studies
should be directed toward identifying the exact components of
the molecular mechanism that are required for this interaction
to occur.
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